Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
S49076 is a multi-kinase inhibitor.1 It inhibits c-Met, Axl, Mer, FGFR1, FGFR2, and FGFR3 (IC50s = 1, 7, 2, 18, 17, and 15 nM, respectively). S49076 inhibits Axl- and c-Met-mediated Akt phosphorylation in MDA-MB-231 cells (IC50s = 33 and <3 nM, respectively). It also inhibits FGFR1, FGFR2, and FGFR3 autophosphorylation in NCI 1703, SNU-16, and RT-112 cells, respectively (IC50s = 50-200 nM). In vivo, S49076 (6.25-50 mg/kg) reduces mean tumor volume in GTL-16 and U87MG mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. 12(9), 1749-1762 (2013).